Chronic Venous Insufficiency: Global and Philippine Prevalence and Disease Burden
Chronic venous insufficiency (CVI) is a highly prevalent global condition affecting approximately 40-84% of the general adult population, with significant geographic variation, though specific Philippine data is notably absent from the current literature.
Global Prevalence
The worldwide burden of CVI is substantial and well-documented across multiple continents 1, 2:
Overall Disease Burden
- Total CVD prevalence globally: 83.6% of screened populations, with 63.9% having visible disease (C1-C6) and 19.7% having symptomatic disease without visible signs (C0s) 2
- A more conservative systematic review estimates pooled prevalence by CEAP stage 1:
- C0s (symptomatic, no visible signs): 9%
- C1 (telangiectasias/reticular veins): 26%
- C2 (varicose veins): 19%
- C3 (edema): 8%
- C4 (skin changes): 4%
- C5 (healed ulcer): 1%
- C6 (active ulcer): 0.42%
United States-Specific Data
The most concrete prevalence data comes from the U.S. 3, 4:
- Over 33 million adults (11 million men and 22 million women aged 40-80) have varicose veins
- Over 2 million adults have advanced chronic venous disease
- Approximate prevalence: 25% for C2-C3 disease and 5% for C4-C6 stages
- Varicose veins specifically affect 16% of men and 29% of women 5
- Telangiectasias occur in 43% of men and 55% of women 5
Geographic Variation
C2 disease (varicose veins) prevalence is highest in Western Europe and lowest in the Middle East and Africa 1. This geographic disparity likely reflects differences in risk factor distribution, diagnostic accuracy, and healthcare resource availability 6.
Philippine-Specific Data
No Philippine-specific prevalence data exists in the current evidence base. This represents a significant gap in epidemiological knowledge for Southeast Asian populations. Given that the Philippines shares risk factors common to developing nations (prolonged standing occupations, limited access to compression therapy) and Western influences (increasing obesity rates), the prevalence likely falls somewhere between Western and Asian estimates, but this remains speculative without local studies.
Disease Burden
Economic Impact
The financial burden is staggering, particularly in developed healthcare systems 3, 4:
- U.S. healthcare costs exceed $3 billion annually for venous disease treatment
- Venous ulcer treatment alone costs >$2.5 billion per year in the United States
- At least 20,556 individuals are newly diagnosed with venous ulcers yearly in the U.S.
- The recurrent nature of venous ulcerative disease drives these high costs, with 15-35% recurrence rates within 2 years post-intervention
Morbidity and Quality of Life Impact
CVI significantly impairs quality of life and increases mortality risk 7:
- CVI is associated with a 46-51% increased risk of all-cause mortality (HR 1.46,95% CI 1.19-1.79, P=0.0003), independent of cardiovascular risk factors 7
- This mortality association was validated in an independent cohort (HR 1.51,95% CI 1.11-2.05, P=0.009) 7
Venous leg ulcers represent the most severe manifestation 8:
- Most chronic leg ulcers are venous in origin, with prevalence approaching 1% of the population 3
- Nearly half of patients experience recurrent episodes, significantly impacting quality of life 8
- VLU is a chronic disease requiring lifelong maintenance 8
Clinical Manifestations Affecting Quality of Life
Patients experience progressive symptoms that worsen with disease severity 5, 9:
- Pain, burning, itching, aching, heaviness, cramping, throbbing
- Leg swelling and restlessness
- Symptoms worsen with prolonged standing and at day's end
- Advanced stages: skin pigmentation changes, eczema, lipodermatosclerosis, ulceration
Key Risk Factors
Established risk factors with strong evidence 1, 6, 9:
- Female sex (OR 2.26,95% CI 2.16-2.36, P<0.001) - the strongest demographic predictor
- Increasing age - prevalence rises substantially with age
- Obesity - increases intra-abdominal pressure
- Prolonged standing occupations - particularly relevant for Philippine workforce
- Positive family history - genetic predisposition
- Pregnancy and parity - cumulative effect with multiple pregnancies
- Caucasian ethnicity - higher prevalence than other ethnic groups
- History of deep vein thrombosis - causes secondary valve damage
Clinical Implications for the Philippines
Healthcare Planning Considerations
Without local prevalence data, healthcare planners should assume:
- At least 20-40% of adults have some form of CVD based on global estimates
- Occupational risk is likely high given prevalence of standing occupations (retail, manufacturing, healthcare)
- Limited access to compression therapy may worsen outcomes compared to Western countries 10
- Screening programs are needed to identify disease early and prevent progression to ulcerative stages
Prevention and Early Intervention
Early identification and treatment are critical because 4, 9:
- The disease is progressive without intervention
- Advanced stages (C4-C6) carry the highest morbidity and cost burden
- Timely diagnosis and treatment can prevent progression to ulcerative disease
- Compression therapy remains the gold standard but requires patient education and compliance support 10, 11
Critical Knowledge Gaps
The absence of Philippine-specific epidemiological data represents a significant limitation for:
- Accurate healthcare resource allocation
- Workforce planning for vascular specialists
- Public health intervention targeting
- Understanding ethnic and environmental risk factor contributions in Southeast Asian populations
Local epidemiological studies are urgently needed to characterize the true burden of CVI in the Philippines and guide evidence-based healthcare policy.